Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUSRE33093 E
Publication typeGrant
Application numberUS 07/272,354
Publication dateOct 17, 1989
Filing dateNov 16, 1988
Priority dateJun 16, 1986
Fee statusPaid
Publication number07272354, 272354, US RE33093 E, US RE33093E, US-E-RE33093, USRE33093 E, USRE33093E
InventorsMichael T. Schiraldi, Martin M. Perl, Howard Rubin
Original AssigneeJohnson & Johnson Consumer Products, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Bioadhesive extruded film for intra-oral drug delivery and process
US RE33093 E
Abstract
A bioadhesive extruded single or multi-layered thin film, especially useful in intra-oral controlled-releasing delivery, having a water soluble or swellable polymer matrix bioadhesive layer which can adhere to a wet mucous surface and which bioadhesive layer consists essentially of .[.40-95.]. .Iadd.20-92.Iaddend.% by weight of a hydroxypropyl cellulose 5-60% of a homopolymer of ethylene oxide, 0-10% of a water-insoluble polymer such as ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and 2-10% of a plasticizer, said film having incorporated therein a medicament, e.g. anesthetics, analgesics, anticaries agents, anti-inflammatories, antihistamines, antibiotics, antibacterials, fungistats, etc.
Images(7)
Previous page
Next page
Claims(9)
What is claimed is:
1. A pharmaceutically acceptable controlled-releasing medicament-containing extruded single or multi-layered thin film, capable of adhering to a wet mucous surface, comprising a water soluble or swellable polymer matrix bioadhesive layer which can adhere to a wet mucous surface and which bioadhesive layer consists essentially of .[.40-95.]..Iadd.20-93.Iaddend.% by weight of a hydroxypropyl cellulose having a molecular weight above 100,000, 5-60% of a homopolymer of ethylene oxide having a molecular weight from 3,000,000 to 5,000,000, 0-10% of a water-insoluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and 2-10% of a plasticizer, said film having incorporated therein a pharmaceutically effective amount of said medicament.
2. The extruded film of claim 1, made in a form which is so thin and flexible when wet as to be unobtrusive to the patient when properly positioned and placed in the patients mouth.
3. The extruded film of claim 2 having a thickness no greater than 0.25 millimeters.
4. The extruded film of claim 1, in single layer form, which also contains up to 10% by weight of a non-soluble polymer selected from the group consisting of ethyl cellulose, polyethylene, polypropylene and carboxymethyl cellulose free acid.
5. The extruded film of claim 1, in multi-layer laminated form, which is addition to the bioadhesive layer also contains a reservoir layer in which at least a major portion of the medicament is contained.
6. The extruded multi-layer film of claim 5 in which the reservoir layer consists essentially of a polymer matrix comprised of both a water soluble or swellable polymer and a non-water soluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and also hydroxypropyl cellulose.
7. The extruded film of claim 1 in multi-layer laminated form, which in addition to the bioadhesive layer also contains an outer protective-barrier membrane layer.
8. The extruded multi-layer film of claim 7 in which the outer protective-barrier membrane layer is thinner than the bioadhesive layer, and said outer protective barrier layer consists essentially of a polymer matrix of a major proportion of a non-water-soluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and a minor proportion of hydroxypropyl cellulose.
9. The extruded multi-layer film of claim 1 in the form of a triple layered laminate containing sodium fluoride for anticaries protection having the following composition:
______________________________________                              Outer                              Protective           Bio-     % w/w     Barrier           adhesive Reservoir Membrane           Layer    Layer     LayerIngredients     (0.1 mm) (0.025 mm)                              (0.025 mm)______________________________________Polyethylene oxide           60.0     --        --homopolymer(MW 3,000,000 minimum)Hydroxypropyl Cellulose           30.0     20.0      24.0(MW 1,000,000)Polyethylene (Low Density)           5.0      --        --Propylene Glycol U.S.P.           3.0      --        --Polyethylene Glycol           2.0      --        --(MW 400)Ethyl Cellulose --       59.0      69.6Caprylic/Capric --        5.0      6.0TriglycerideSodium Flouride --       16.0      0.4           100.0    100.0     100.0______________________________________
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a controlled-releasing medicament-containing preparation for intra-oral use, and is more especially concerned with such a preparation (and the process of using it) in the form of a very thin extruded thermoplastic film (which can be in single layer or laminated multi-layer form) having at least one bioadhesive layer containing .[.40-95.]..Iadd.20-93.Iaddend.% of a thermoplastic cellulose ether and 5-60% of a homopolymer of ethylene oxide which can adhere to the mucosa of the oral cavity. The extruded film drug delivery system of the present invention, which has incorporated therein the medicament to be dispensed, is so thin and flexible when wet as to be unobtrusive to the patient after it has been properly positioned and placed in the mouth.

2. Description of the Prior Art

Several systems have previously been described which pertain to the delivery of drugs into the oral cavity. These include:

1. Treatment of periodontal disease with tetracycline, chlorhexidine or metronidazole loaded into hollow cellulose acetate fibers. These fibers are packed in the periodontal pockets and provide controlled release of the drug to the infected area.

2. Cast films containing ethyl cellulose/propylene glycol with chlorhexidine or metronidazole for treatment of periodontal disease.

3. An orthodontic appliance with a hydroxyethyl methacrylate/methyl methacrylate copolymer (HEMA/MMA) matrix. Sodium fluoride is incorporated into the HEMA/MMA matrix to provide sustained fluoride release and enhanced anticaries activity. HEMA/MMA with fluoride may also be attached to the tooth in the form of a wafer-like tablet.

4. Silicone/ethyl cellulose/polyethylene glycol films containing sodium fluoride are applied as coatings on orthodontic bands or in chewing gum. Controlled release of fluoride and anticaries activity is claimed. The above systems are discussed in the "The Compendium of Continuing Education" Vol VI, No. 1, January 1985 p. 27-36 review article "Controlled Drug Delivery: A New Means of Treatment of Dental Disease", by J. Max Goodson, D.D.S., Ph.D. of the Forsyth Dental Center. Other systems, described in GB patent application No. 2,042,888 and U.S. Pat. Nos. 4,292,299/4,226,848 (Teijin Ltd., Japan), use combinations of cellulosic and polyacrylate polymers. The preferred materials are hydroxypropyl cellulose ("Klucel") and a copolymer of acrylic acid ("Carbopol") that is administered in the form of thin tablets (discs), granules or powder. Other polymers that might be added are vinyl copolymers, polysaccharides, gelatin and collagen. U.S. Pat. No. 4,517,173 (Nippon Soda Co. Ltd, Japan) uses various celluloses in a multi-layered non-extruded cast film preparation.

Examples of prior art products currently on the market include ointments such as ORABASE* with Benzocaine (Squibb), Kenalog* (Triamcinolone Acetonide) in ORABASE* (Squibb) and Mycostatin* (Nystatin) ointment (Squibb).

The prior art products and delivery systems described above are useful but have the following disadvantages:

Tablets, appliances, hollow fibers are "bulky" in the mouth, are difficult to keep in place and inconvenient to apply.

Ethyl cellulose and/or silicone films do not adhere to mucosal tissue.

Ointments (i.e., ORABASE*) have an unpleasant feel and do not last very long.

Except for ORABASE*, all the foregoing systems require professional application to the tooth or periodontal pockets.

The bioadhesive film of the present invention alleviates many of the above problems. It may be applied easily by the consumer. It has very little or no mouthfeel, it has good adhesion to the mucosal tissues, and provides controlled release of the medicament.

OBJECT OF THE INVENTION

It is an object of this invention to provide an extruded film that is an effective and convenient intra-oral drug delivery system and method for applying and delivering controlled dosages of therapeutic agents into the oral cavity. This technology may also be extended for controlled drug delivery in skin care, gynecological applications, wound care and like uses.

SUMMARY OF THE INVENTION

The invention involves a pharmaceutically acceptable controlled-releasing medicament-containing extruded single or multi-layered thin film, capable of adhering to a wet mucous surface, comprising a water soluble or swellable polymer matrix bioadhesive layer which can adhere to a wet mucous surface and which bioadhesive layer consists essentially of .[.40-95.Iadd.20-93.Iaddend.% by weight of hydroxypropyl cellulose 5-60% of a homopolymer of ethylene oxide, 0-10% of a water-insoluble polymer selected from the group consisting of ethyl cellulose, propyl cellulose, polyethylene and polypropylene, and 2-10% of a plasticizer, said film having incorporated therein a pharmaceutically effective amount of said medicament.

The present invention is directed to an extruded single or multi-layered laminated thin (1-10 mils or 0.025-0.25 mm) film, composed of selected water soluble and/or insoluble polymers. Various therapeutic agents are incorporated into the film during manufacture which are useful for treatment of oral disorders (i.e., denture discomfort, caries, periodontal disease, aphthous ulcers, etc.).

The extruded film of the present invention must have at least one bioadhesive layer, but may also have a reservoir layer and/or an outer protective barrier membrane layer. The therapeutic agent may be incorporated into any or all of the layers. When properly formulated and fabricated, these films will adhere to wet mucosal surfaces, provide a protective barrier for injured tissue and deliver controlled/sustained dosages of medication to the infected areas. The film may be designed for localized drug delivery (i.e., the periodontal pocket, an aphthous lesion), or may allow diffusion of the drug into the oral cavity.

An example of a non-localized system would be the delivery of sodium fluoride for caries prevention. A single or laminated film with good adhesion to the tooth or mucosal tissue may be employed in which the fluoride release rates may be controlled by varying film solubilities and/or concentration of fluoride in a multi-layered film.

An example of a localized application of medication would be in the treatment of aphthous lesions. A laminated two layer film with benzocaine incorporated into the adhesive layer would directly contact the injured mucosa. The outer layer would consist of non-soluble/non-adhesive polymers that provide durability, protection and directs the delivery of benzocaine toward the lesion.

The film forming polymers that are useful in this invention are selected from pharmaceutical grade materials, or those that are considered generally regarded as safe (GRAS) as food additives. They include, hydroxypropyl cellulose, and polyethylene oxide homopolymers. Small amounts of other polymers, e.g., polyvinyl ether-maleic acid copolymers and the like may be used in small amounts as well, replacing a small portion of the other polymers. The above materials are either water soluble of swellable and are most useful in the bioadhesive layer of the film. Various non-soluble polymers may also be incorporated for modification of the film's permeability properties, such as ethyl cellulose, propyl cellulose, polyethylene, polypropylene and carboxymethylcellulose (free acid). By varying the ratios of the above polymers both the solubility and the adhesive properties of each layer of film may be controlled. Therefore, depending on the desired delivery rate, the type of disorder to be treated, the area to be treated and the medication being administered it is possible to custom design the film by selecting and blending various polymers. The final film product may also be fabricated into flexible tapes of varied thickness and width, "spots" of different sizes and shapes or other pre-shaped forms.

The medicaments and pharmaceutical agents set forth in the prior art discussed above may generally be delivered by the drug delivery system of the present invention. Usable medicaments are those which are capable of withstanding the heats and pressures generated in the extrusion process involved in making the film of the present invention. Preferred medicaments include:

Anesthetics/Analgesics-benzocaine, dyclonine HCl, phenol, aspirin, phenacetin, acetaminophen, potassium nitrate, etc.

Anticaries Agents-sodium fluoride, sodium monofluorophosphate, stannous fluoride, etc.

Anti-inflammatories-hydrocortisone acetate, triamcinolone acetonide, dipotassium, glycyrrhizinate, etc.

Antihistamines-chlorpheniramine maleate, ephedrine HCL, diphenhydramine HCL, etc.

Antibiotics-i.e., tetracycline, doxycycline hyclate, meclocycline, minocycline, etc.

Antibacterials-chlorhexidine, cetyl pyridinium chloride, benzethonium chloride, dequalinium chloride, silver sulfadiazene, phenol, thymol, hexedine, hexetidine, alexidine, etc.

Fungistats-nystatin, miconazole, ketoconazole, etc.

The above are illustrative examples of therapeutic agents that are used to treat oral disorders. The present invention is not to be limited to these specific materials especially where it is intended to deliver drug outside of the oral cavity e.g. to skin where other drugs may be desirable.

The film of the present invention has the advantage of being an extruded film, rather than a cast film. When a multi-layered film is involved, the different layers can be coextruded and then laminated together, or else each layer can be separately extruded one on the other, and then laminated together, so that the final multi-layered film is still very thin. The films of the present invention can be made in thicknesses of only 1-10 mils or 0.025-0.25 mm. The films are so thin that when placed in the mouth after they become wet they soon become unobtrusive, and hardly noticeable by most patients.

The film must always have a bioadhesive layer, which enables it to adhere to wet mucosal surfaces. The bioadhesive layer has .[.40-95.Iadd.20-93.Iaddend.% of hydroxypropyl cellulose, 5-60% of a homopolymer of ethylene oxide and 2-10% of a glycol plasticizer (all percents are % by weight).

The Hydroxypropyl cellulose (HPC), useful for purposes of the present invention is commercially available from Hercules, Inc. (Wilmington, DE) under the tradename KLUCEL*. Preferred grades include Klucel MF, with a molecular weight around 600,000 and having a viscosity of 4,000-6,000 cps (Brookfield) in 2 percent water solutions, or Klucel HF, having a molecular weight around 1,000,000 and viscosity of 1500-2500 cps in 1 percent water solution. In general, any HPC having a Molecular Weight above about 100,000 is useful for purposes of this invention.

The homopolymer of ethylene oxide useful for purposes of the present invention has a relatively high molecular weight, i.e., above 100,000 and preferably above 3,000,000. Such polymers are commercially available from various sources. The Union Carbide Corporation material, "Polyox WSR-301", which has a molecular weight of approximately 4,000,000-5,000,000 is most preferred for purposes of the present invention.

The "plasticizer" useful for purposes of the present invention are selected from glycols such as propylene glycol and polyethylene glycol; polyhydric alcohols such as glycerin and sorbitol; glycerol esters such as glycerol triacetate; fatty acid triglycerides such as NEOBEE* M-5 and MYVEROLS*; mineral oil; vegetable oils such as castor oil, etc.

For the uses for the present invention contemplated here, the plasticizer should be non-toxic. The purpose of the plasticizer is to improve polymer melt processing by reducing the polymer melt viscosity and to impart flexibility to the final product.

The preferred plasticizer for use in the present invention is either propylene glycol or polyethylene glycol (such as is available from Union Carbide Corporation as their series of Carbowaxes which runs from 200 to 600 molecular weight, of which we prefer to use Carbowax 400, which has a molecular weight of 400, average.

In addition to the polymers and plasticizer which are required ingredients of the films of the present invention, minor amounts of other non-essential but customary ingredients will often be used if desired, e.g., antioxidants, preservatives, flavors, colorants.

DETAILED DESCRIPTION

The following examples will serve to illustrate the present invention in greater detail. The units shown in the examples are parts by weight. The thickness of the layers is expressed in either mils (0.001 inches) or millimeters. For easy conversion, 4 mils is approximately equal to 0.1 mm.

EXAMPLE 1

Triple Layered Laminate Containing Sodium Fluoride for Anticaries Protection

This three layered film laminate is comprised of a "bioadhesive" layer, a sodium fluoride "reservoir" layer and, an "outer protective barrier membrane" layer, in which the composition and thickness of each layer are as shown below:

______________________________________                              Outer                              Protective           Bio-     % w/w     Barrier           adhesive Reservoir Membrane           Layer    Layer     Layer           (4 mils) (1 mil)   (1 mil)Ingredients     (0.1 mm) (0.025 mm)                              (0.025 mm)______________________________________Polyethylene oxide           60.0     --        --homopolymer (UnisonCarbide-Polyox* WSR-301)Hydroxypropyl Cellulose           30.0     20.0      24.0(Hercules, Inc.-Klucel* MF)Polyethylene (Allied           5.0      --        --Chemical-6A)(Low Density)Propylene Glycol, U.S.P.           3.0      --        --Polyethylene Glycol           2.0      --        --400 (Union Carbide)Ethyl Cellulose (Hercules,           --       59.0      69.6Inc.-N100F)Caprylic/Capric --        5.0      6.0Triglyceride(PVOIncorporated-Neobee M-5)Sodium Fluoride, U.S.P.           --       16.0      0.4           100.0    100.0     100.0______________________________________

The process used to make the above laminate was:

a. Powder Blending-Each layer is made separately and all ingredients used therein except propylene glycol and Neobee M-5 (liquid plasticizers) are placed in a Patterson Kelley (PK) V-blender equipped with liquid addition capabilities. The ingredients which are all powders are blended for approximately 10-15 minutes while the liquid plasticizer is slowly added to the mix. Three separate powder blends are made, one for each layer.

b. Extrusion Process-A standard Johnson 2-1/2 inch vinyl/polyolefin extruder equipped with a single three stage screw was used to extrude the "powder blend". The temperature conditions for the water soluble powders are however quite different from those used for vinyls and polyolefins. The temperature (C.) profile for the "reservoir" and "membrane layers" of the triple laminate was as follows:

______________________________________  Barrel Zone 1            100  Barrel Zone 2            125  Barrel Zone 3            135  Barrel Zone 4            145  Barrel Zone 5            160  Barrel Zone 6            170  Adapter   180  Die Zone 1            180  Die Zone 2            180  Die Zone 3            180______________________________________

The films which had a width of 18 inches, were extruded at approximately 20 feet/minute through a flat lipped die. The temperature profile for the "bioadhesive layer" was:

______________________________________  Barrel Zone 1            125  Barrel Zone 2            140  Barrel Zone 3            165  Barrel Zone 4            170  Barrel Zone 5            185  Barrel Zone 6            185  Adapter   185  Die Zone 1            185  Die Zone 2            185  Die Zone 3            185______________________________________

Each layer is extruded separately with the first layer extruded as a "free film". Successive layers are extruded onto each other and laminated by passing them through heated stainless steel rollers.

Test Results:

In vitro fluoride ion release studies were conducted on samples of the above described triple laminate film measuring 0.5 cm1.25 cm (0.625 cm2) according to the following procedures:

The test sample is adhered to a glass slide by prewetting the film and placing the bioadhesive layer on the glass surface. The slide is then immersed in a beaker containing 100 ml of distilled water with continuous stirring. Five milliliter aliquots are withdrawn from the solution, at prescribed time intervals, and analyzed for fluoride content with an Orion Ionanalyzer equipped with a fluoride specific electrode. Release rates are then calculated from the data.

The results obtained indicated fluoride release rates in the order of 0.05-0.2 mgs/cm2 /hr for 24 hours. This falls within the desired range for maintaining constant low levels of fluoride in the mouth and enhanced anticaries activity. Release rates may be tailored to desired use levels by modification of the film composition and construction.

EXAMPLE 2

Single Layer Adhesive Film Containing Hydrocortisone Acetate (0.5%) As An Anti-Inflammatory Agent

The composition of the film, which was 0.1 mm. thick, was as follows:

______________________________________Ingredients           % w/w______________________________________Ethylene Oxide Homopolymer                 59.4(Polyox* WSR-301)Hydroxypropyl Cellulose                 30.0(Klucel* MF)Polyethylene (AC-6A)  5.0Propylene Glycol      3.0Polyethylene Glycol 400                 2.0Butylated Hydroxy Toluene (BHT)                 0.1FCC (preservative)Hydrocortisone Acetate                 0.5                 100.0______________________________________

The powder blending process and extruder conditions used were the same as those described in Example I for the "bioadhesive layer" of the sodium fluoride trilaminate. In vitro tests were performed on the above film and demonstrated a prolonged drug release pattern.

EXAMPLE 3

Single Layer Adhesive Film Containing Triamcinolone Acetonide (0.1%) As An Anti-Inflammatory

The composition of the film, which was 0.1 mm. thick, was as follows:

______________________________________Ingredients          % w/w______________________________________Ethylene Oxide Homopolymer                59.9(Polyox WSR-301)Hydroxypropyl Cellulose                29.9(Klucel MF)Polyethylene (AC-6A) 5.0Propylene Glycol     3.0Polyethylene Glycol 400                2.0BHT                  0.1Triamcinolone Acetonide                0.1                100.0______________________________________

The powder blending process and extruder conditions used to make the film of this Example 3 were the same as those of the "bioadhesive layer" of Example I.

Other desired active medicament ingredients may be incorporated into the adhesive films of any of Examples 1-3 in place of the particular medicament used in said examples. These include Benzocaine (analgesic), Potassium nitrate (analgesic), Silver sulfadiazene (antimicrobial),

Chlorhexidine (antimicrobial), miconazole nitrate (antifungal), Benzethonium chloride (antimicrobial), Tetracycline (antibiotic) and other similar therapeutic compounds.

EXAMPLE 4

Analgesic Films with Potassium Nitrate

This example shows 5 variations of the film having different solubilities, resulting in different release rates.

______________________________________         % w/wIngredients     1      2       3    4     5______________________________________Polyethylene oxide           23.75  57.00   55.00                               55.00 57.00homopolymer (Polyox*WSR-301)Hydroxypropyl Cell-           68.30  --      --   --    --ulose, N.F. (Klucel* HF)Hydroxypropyl Cell-           --     28.40   29.90                               22.40 22.40ulose, N.F. (Klucel* MF)Ethyl Cellulose --     4.75    5.00 12.50 12.50Polyethylene Glycol 400           1.90   1.90    2.00 2.00  2.00Polyethylene Glycol 8000           0.95   --      --   --    --Propylene Glycol, U.S.P.           --     2.85    3.00 3.00  3.00BHT, F.C.C.     0.10   0.10    0.10 0.10  0.10Potassium Nitrate, F.C.C.           5.00   5.00    5.00 5.00  3.00______________________________________

The above ingredients are blended in a Patterson-Kelly powder blender equipped with liquid addition capabilities. The resulting powder blend is then extruded into film on a Killion or Johnson vinyl extruder using processing procedures similar to those of the bioadhesive layer of Example I.

example 5

Anesthetic Films with Benzocaine (Laminate)

This is an example of a two-layer laminate. The processing conditions used were similar to those of the bioadhesive layer and outer protective barrier membrane layer of Example I.

______________________________________A.      Inner medicated bioadhesive layer   Polyoxyethylene Homopolymer                        57.00   (Polyox* WSR-301)   Hydroxypropyl Cellulose, N.F.                        28.40   (Klucel* MF)   Polyethylene (AC-6A) 4.75   Propylene Glycol, U.S.P.                        2.85   Polyethylene Glycol 400                        1.90   BHT, F.C.C.          0.10   Benzocaine, U.S.P.   5.00                        100.00B.      Outer protective/barrier layer   Hydroxypropyl Cellulose                        78.00   (Klucel* MF)   Ethyl Cellulose      20.00   Polyethylene Glycol 400                        2.00                        100.00______________________________________

Part A was extruded on a Johnson extruder followed by subsequent extrusion and lamination of Part B to A.

Samples were applied to oral lesions, and provided profound anesthetic effects (lasting several hours) within minutes of application.

The identical two-layer laminate may also be made by coextruding the inner medicated bioadhesive layer (Part A) and the outer protective barrier layer (Part B) through separate die slots within a coextruder and laminating the two layers together.

EXAMPLE 6

Anesthetic Films with Phenol and Dyclonine HCl

Four variations of a single layer bioadhesive film were made as shown below:

______________________________________Ingredients      1      2        3    4______________________________________Polyethylene oxide homo-            59.10  54.00    59.70                                 58.20polymer (Polyox* WSR-301)Hydroxypropyl Cellulose            29.45  26.91    29.75                                 29.00(Klucel HF)Ethyl Cellulose  4.93   4.50     4.98 4.85Propylene Glycol, U.S.P.            2.96   2.70     2.99 2.91Polyethylene Glycol 400            1.97   1.80     1.99 1.94BHT, F.C.C.      0.09   0.09     0.09 0.10Phenol, U.S.P.   1.50   --       --   --Dyclonine HCl    --     10.00    0.50 3.00______________________________________

Following the procedures for the bioadhesive layer of Example I, the powders were blended in P-K blender equipped with liquid addition capabilities. Resulting powders were extruded on a Killion laboratory-sized extruder.

EXAMPLE 7

Silver Sulfadiazene Films-Antimicrobial

Three different single-layered bioadhesive films containing 1.0% 0.5% and 0.5% respectively of silver sulfadiazene (SSD) were prepared on a heated Carver laboratory press (designed to simulate extruded conditions) as shown below.

______________________________________              % w/wIngredients          A       B______________________________________Polyethylene oxide homopolymer                60.00   60.00(Polyox* WSR-301)Hydroxypropyl Cellulose                28.9    29.4(Klucel* HF)Polyethylene (AC-6A) 5.0     5.0Propylene Glycol, U.S.P.                3.0     3.0Polyethylene Glycol 400                2.0     2.0BHT, F.C.C.          0.1     0.1Silver Sulfadiazine  1.0     0.5                100.0   100.0______________________________________

Effects on wound repair and activity against Staphylococcus aureus were evaluated in the guinea pig model. Full-thickness excisions were inoculated with 3.8105 organisms, (Staph. aureus) and wound surface microbiology samples taken 10 minutes and 24 hours after treatment. Test films were placed on the wound and covered with BIOCLUSIVE* Transparent Dressings secured with elastic tape. Wound contraction was measured over an eight-day period using OPTOMAX* Computer-Assisted Image Analysis. The three films tested were the following:

A. 1.0% Silver Sulfadiazene, 125 C./2 minutes/4 tons

B. 0.5% Silver Sulfadiazene, 125 C./2 minutes/4 tons

C. 0.5% Silver Sulfadiazene, 150 C./3 minutes/4 tons

SILVADENE Cream and an untreated occluded control. The results indicated that:

1. SILVADENE* treated wounds significantly inhibited full-thickness wound contraction.

2. Film A, B and C inhibited wound contraction relative to that of BIOCLUSIVE* dressed wounds.

3. The three SSD films each permitted substantially faster wound contraction than that of wounds treated daily with SILVADENE* cream.

4. All films were very active against S. Aureus 24 hours after inoculation.

The films may be scaled up by using an extruder. This example demonstrates the feasibility of such a film to perform its intended purpose. Use of a press for larger samples would result in a non-uniform and lower-quality film than an extruded film.

Based on the above findings, the films were very effective antibacterial agents, while mildly inhibiting wound contraction. They offer clinicians a convenient and more effective delivery system for antimicrobials which can be place in wounds beneath any dressing or can be laminated to any acceptable dressing face.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4292299 *Jul 7, 1980Sep 29, 1981Teijin LimitedSlow-releasing medical preparation to be administered by adhering to a wet mucous surface
US4421738 *Mar 18, 1982Dec 20, 1983Eisai Co., Ltd.Sugar-coated tablet containing fat-soluble pharmaceutical material
US4517173 *Sep 25, 1981May 14, 1985Nippon Soda Co. Ltd.Mucous membrane-adhering film preparation and process for its preparation
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US4997830 *Feb 7, 1990Mar 5, 1991The Research Foundation Of State University Of New YorkPharmaceutical composition for the treatment of periodontitis
US5064650 *Apr 4, 1989Nov 12, 1991Southwest Research InstituteOuter shell insoluble at preselected salttconcentration but dissolves in mouth and nontoxic adhesive
US5112620 *Sep 20, 1990May 12, 1992Mikkur, Inc.Blend of polyether and water soluble salt of maleic acid or anhydride copolymer with methyl vinyl ether with anesthetic and steroid
US5114718 *Sep 20, 1990May 19, 1992The Procter & Gamble CompanyBiocompatible polymer containing drug for insertion into the periodontal pocket
US5133971 *Oct 2, 1990Jul 28, 1992Phoebe CopelanPersonal dental hygiene assembly
US5135752 *Oct 14, 1988Aug 4, 1992Zetachron, Inc.Buccal dosage form
US5155144 *Oct 29, 1990Oct 13, 1992Manganaro James LPolysaccharide-based porous sheets
US5262164 *Nov 17, 1989Nov 16, 1993The Procter & Gamble CompanyInsertion into or around the tooth cavity the drug monolein mixed with vitamins, antiiinflammatory agents, antibiotics, peroxides, anesthetic agents and microbactericides
US5288532 *Oct 27, 1992Feb 22, 1994Viskase CorporationTransferable modifier-containing film
US5364634 *Nov 8, 1991Nov 15, 1994Southwest Research InstituteMouths; drug delivery
US5374457 *Oct 1, 1993Dec 20, 1994Viskase CorporationTransferable modifier-containing film
US5382391 *Sep 23, 1993Jan 17, 1995Viskase CorporationMethod for producing transferable modifier-containing film
US5447725 *Jun 11, 1993Sep 5, 1995The Procter & Gamble CompanyMethods for aiding periodontal tissue regeneration
US5700478 *Aug 19, 1994Dec 23, 1997Cygnus, Inc.Comprising water soluble polymer and miscible water soluble plasticizer having specified properties
US5714165 *Apr 1, 1992Feb 3, 1998Mikkur, Inc.Blend of polyoxyethylene glycol and water soluble salt of copolymer of methyl vinyl ether and maleic (acid or anhydride)
US5851551 *Jun 21, 1994Dec 22, 1998The Gillette CompanySustained-release matrices for dental application
US5894017 *Jun 6, 1997Apr 13, 1999The Procter & Gamble CompanyDelivery system for an oral care substance using a strip of material having low flexural stiffness
US5906814 *Oct 22, 1996May 25, 1999The Andrew Jergens CompanyTopical film-forming compositions
US5906834 *Oct 9, 1996May 25, 1999The Gillette CompanyColor changing matrix as wear indicator
US6231957May 6, 1999May 15, 2001Horst G. ZerbeRapidly disintegrating flavor wafer for flavor enrichment
US6261599Jul 23, 1999Jul 17, 2001Euro-Celtique, S.A.Sustained release
US6335033Jul 22, 1999Jan 1, 2002Euro-Celtique, S.A.Melt-extrusion multiparticulates
US6375963Jun 15, 2000Apr 23, 2002Michael A. RepkaBioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US6419906 *Mar 12, 2001Jul 16, 2002Colgate Palmolive CompanyStrip for whitening tooth surfaces
US6503486 *Feb 22, 2002Jan 7, 2003Colgate Palmolive CompanyStrip for whitening tooth surfaces
US6514483 *Feb 22, 2002Feb 4, 2003Colgate Palmolive CompanyStrip for whitening tooth surfaces
US6551579May 29, 2001Apr 22, 2003The Procter & Gamble CompanyDelivery systems for a tooth whitener
US6562363Sep 28, 1998May 13, 2003Noven Pharmaceuticals, Inc.Bioadhesive compositions and methods for topical administration of active agents
US6566350 *May 21, 2001May 20, 2003Showa Yakuhin Kako Co., Ltd.Minocycline-containing compositions
US6582708Jun 28, 2000Jun 24, 2003The Procter & Gamble CompanyTooth whitening substance which comprises a high concentration of water, a peroxide, a gelling agent, and carrier materials. The tooth whitening substance will remain stable when stored as a thin layer. The present invention also relates to a
US6638881Dec 22, 2000Oct 28, 2003Combe IncorporatedDental adhesive device and method of producing same
US6660292Jun 19, 2001Dec 9, 2003Hf Flavoring Technology LlpRapidly disintegrating flavored film for precooked foods
US6682721Feb 13, 2001Jan 27, 2004Lg Household & Healthcare Ltd.Hydrophilic glass polymer as an adhesive layer in a matrix type on a backing layer and peroxide whitening agent
US6689344Sep 13, 2002Feb 10, 2004Lg Household & Healthcare Ltd.Patches for teeth whitening
US6706281Jan 2, 2002Mar 16, 2004Euro-Celtique, S.A.Melt-extrusion multiparticulates
US6743442Feb 6, 2001Jun 1, 2004Euro-Celtique, S.A.Bioavailability; sustained release
US6780401May 27, 2003Aug 24, 2004Lg Household & Healthcare Ltd.Using peroxy compound in adhesive matrix; patch
US6860736Feb 19, 2004Mar 1, 2005Ultradent Products, Inc.Oral treatment devices that include a thin, flexible barrier layer and an endoskeleton treatment or adhesive composition
US6884426Dec 17, 2002Apr 26, 2005The Procter & Gamble Co.Methods for whitening teeth
US6946142Jun 20, 2002Sep 20, 2005Lg Household & Healthcare Ltd.Multi-layer patches for teeth whitening
US6949240May 23, 2002Sep 27, 2005The Procter & Gamble CompanyStrip impregnated with peroxy compound
US6964571Nov 4, 2003Nov 15, 2005Ultradent Products, Inc.Pre-shaped dental trays and treatment devices and methods that utilize such dental trays
US6981874Feb 19, 2004Jan 3, 2006Ultradent Products, Inc.Dental bleaching compositions and devices having a solid activation adhesive layer or region and bleaching gel layer or region
US6997708Dec 5, 2003Feb 14, 2006Ultradent Products, Inc.Treatment compositions and strips having a solid adhesive layer and treatment gel adjacent thereto
US7004756Jan 24, 2003Feb 28, 2006Ultradent Products, Inc.Pre-shaped dental trays and treatment devices and methods that utilize such dental trays
US7011523Oct 22, 2003Mar 14, 2006Ultradent Products, Inc.Bleaching compositions and devices having a solid adhesive layer and bleaching gel adjacent thereto
US7018622Oct 24, 2002Mar 28, 2006The Procter & Gamble CompanyPackaged product for use with tooth whitening systems that is storage stable in absence of light
US7040897May 23, 2003May 9, 2006Ultradent Products, Inc.Thin, flexible membrane dental trays and systems and methods utilizing such trays
US7048543May 27, 2003May 23, 2006Ultradent Products, Inc.A shaped dental bleaching device contains adhesion agent for increasing adhesion to teeth when moistened by saliva or water; polyvinyl pyrrolidone adhesives; kits; dentistry
US7052275Aug 22, 2003May 30, 2006Ultradent Products, Inc.Kits and methods for bleaching and desensitizing teeth
US7056118Aug 22, 2003Jun 6, 2006Ultradent Products, Inc.Compositions and devices having a tray-like configuration for delivering a medicament and methods of manufacturing and using such compositions and devices
US7059857Aug 8, 2003Jun 13, 2006Ultradent Products, Inc.Substantially solid desensitizing compositions and devices having a tray-like configuration and methods of manufacturing and using such compositions and devices
US7059858Feb 19, 2004Jun 13, 2006Ultradent Products, Inc.Universal tray design having anatomical features to enhance fit
US7074042May 27, 2003Jul 11, 2006Ultradent Products, Inc.increased adhesiveness to teeth when moistened with saliva or water; tray shape of the dental bleaching device facilitates placement of the device over a person's teeth
US7122199Apr 6, 2005Oct 17, 2006The Procter & Gamble CompanyMethods for whitening teeth
US7132113Apr 16, 2002Nov 7, 2006Intelgenx Corp.High speed disintegration; mixture of hydroxypropyl cellulose and starch
US7192280Feb 19, 2004Mar 20, 2007Ultradent Products, Inc.Dental bleaching devices having a protective adhesive region
US7247022Jan 31, 2005Jul 24, 2007Ultradent Products, Inc.Dental tray system with releasable hold inner and outer dental trays
US7264471May 5, 2004Sep 4, 2007Ultradent Products, Inc.Methods and kits for bleaching teeth while protecting adjacent gingival tissue
US7338664Sep 15, 2003Mar 4, 2008The Gillette CompanyA sustained-release matrix for dental application includes either an anti-microbial agent or a colorant that is released from the matrix when the matrix contacts water; include a water-soluble polymer and a water-insoluble support resin
US7357891Jan 30, 2004Apr 15, 2008Monosol Rx, LlcProcess for making an ingestible film
US7425292Feb 14, 2002Sep 16, 2008Monosol Rx, LlcThin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US7452209May 2, 2005Nov 18, 2008Ultradent Products, Inc.Exoskeleton support for placement of a dental treatment strip
US7470397Oct 22, 2004Dec 30, 2008Adhesives Research, Inc.Disintegratable films for diagnostic devices
US7481653Feb 9, 2005Jan 27, 2009Oratech LcPreshaped thin-walled dental trays and methods of manufacturing and using such trays
US7510727Dec 23, 2003Mar 31, 2009Purdue Pharma L.P.Unit dose sustained-release oral dosage form of melt extruded particles of specified particle size comprising a drug such as an opiod, one or more retardants, and an optional water insoluble binder
US7576067Dec 1, 2004Aug 18, 2009Isis Pharmaceuticals, Inc.Pulsatile release compositions and methods for enhanced intestinal oligonucleotide drug absorption
US7625210Aug 9, 2004Dec 1, 2009Ultradent Products, Inc.Treatment devices for providing oral treatments and kits and methods that utilize such treatment devices
US7666337May 28, 2004Feb 23, 2010Monosol Rx, LlcPolyethylene oxide-based films and drug delivery systems made therefrom
US7727466Nov 21, 2008Jun 1, 2010Adhesives Research, Inc.test film made of water soluble two polymers, one having high molecular weight and the other having low molecular weight such as hydroxypropyl cellulose, hydroxymethyl propyl cellulose; for detecting chorionic gonadotropin, glucose, prostate specific antigen, metabolites; pesticides; or toxin; monolayer
US7766658Nov 30, 2004Aug 3, 2010Align Technology, Inc.Systems and methods for intra-oral diagnosis
US7785572May 28, 2004Aug 31, 2010Lg Household And Health Care Ltd.Method and device for teeth whitening using a dry type adhesive
US7824588Apr 14, 2008Nov 2, 2010Monosol Rx, LlcWater degradation; controlled drying; digestible film containing water soluble polymer
US7862802Aug 10, 2004Jan 4, 2011Lg Household & Health Care Ltd.adhesive matrix layer contains a peroxide teeth whitening agent and a hydrophilic glassy polymer that provides strong adhesion to teeth when hydrated and little or no adhesion prior to hydration
US7910641Dec 14, 2006Mar 22, 2011Monosol Rx, LlcPH modulated films for delivery of actives
US7947508Oct 31, 2007May 24, 2011Align Technology, Inc.Systems and methods for intra-oral diagnosis
US7972618Sep 20, 2007Jul 5, 2011Monosol Rx, LlcEdible water-soluble film containing a foam reducing flavoring agent
US8007277Aug 9, 2007Aug 30, 2011Ultradent Products, Inc.Non-custom dental treatment trays and mouth guards having improved anatomical features
US8017150Apr 22, 2008Sep 13, 2011Monosol Rx, LlcPolyether combined with hydrophilic cellulosic material; demonstrates non-self-aggregating, uniform heterogeneity; mucosally adhesive water soluble product containing analgesic opiate; preventing air pocket formation during production
US8075309Oct 31, 2007Dec 13, 2011Align Technology, Inc.Systems and methods for intra-oral drug delivery
US8075872Feb 6, 2006Dec 13, 2011Gruenenthal GmbhHeat pressing a mixture of an active ingredient with abuse potential, a high strength polymer, and a wax into a controlled release dosage form
US8114383Nov 20, 2003Feb 14, 2012Gruenenthal GmbhAbuse-proofed dosage form
US8114384Jul 14, 2004Feb 14, 2012Gruenenthal GmbhProcess for the production of an abuse-proofed solid dosage form
US8173152Mar 22, 2007May 8, 2012Auxilium Us Holdings, LlcStabilized compositions containing alkaline labile drugs
US8192722Jun 17, 2008Jun 5, 2012Grunenthal GmbhAbuse-proof dosage form
US8202091Aug 29, 2008Jun 19, 2012Ultradent Products, Inc.Dental treatment trays comprising silicone elastomeric material
US8277215Jun 5, 2006Oct 2, 2012Ultradent Products, Inc.Universal non-custom dental tray having anatomical features to enhance fit
US8282954Dec 15, 2008Oct 9, 2012Monosol Rx, LlcMethod for manufacturing edible film
US8309060Jan 9, 2012Nov 13, 2012Grunenthal GmbhAbuse-proofed dosage form
US8323889Jun 17, 2008Dec 4, 2012Gruenenthal GmbhProcess for the production of an abuse-proofed solid dosage form
US8383152Jan 23, 2009Feb 26, 2013Gruenenthal GmbhPharmaceutical dosage form
US8420056Oct 11, 2011Apr 16, 2013Grunenthal GmbhAbuse-proofed dosage form
US8439674Dec 13, 2011May 14, 2013Align Technology, Inc.Systems and methods for intra-oral drug delivery
US8444413Aug 29, 2011May 21, 2013Ultradent Products, Inc.Non-custom dental treatment trays having improved anatomical features
US8465759Mar 22, 2007Jun 18, 2013Auxilium Us Holdings, LlcProcess for the preparation of a hot-melt extruded laminate
US8475832Aug 7, 2009Jul 2, 2013Rb Pharmaceuticals LimitedSublingual and buccal film compositions
US8557286Apr 20, 2000Oct 15, 2013Euroceltique, S.A.Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix
US8603514Jul 10, 2007Dec 10, 2013Monosol Rx, LlcUniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8613285Apr 9, 2010Dec 24, 2013Philip Morris Products S.A.Extrudable and extruded compositions for delivery of bioactive agents, method of making same and method of using same
US8647314 *Feb 27, 2009Feb 11, 2014Lts Lohmann Therapie-Systeme AgGingival wafer
US8647607Apr 28, 2006Feb 11, 2014Lg Household & Health Care Ltd.Patches for teeth whitening
US8652446Nov 19, 2003Feb 18, 2014Lg Household & Healthcare Ltd.Apparatus and method for whitening teeth
US8663687May 13, 2010Mar 4, 2014Monosol Rx, LlcFilm compositions for delivery of actives
US8663696Aug 17, 2012Mar 4, 2014Monosol Rx, LlcFilm delivery system for tetrahydrolipstatin
US8685437Mar 26, 2009Apr 1, 2014Monosol Rx, LlcThin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8721332Jan 15, 2013May 13, 2014Ultradent Products, Inc.Non-custom dental treatment trays having improved anatomical features
US8722086Mar 7, 2008May 13, 2014Gruenenthal GmbhDosage form with impeded abuse
US8815289May 23, 2013Aug 26, 2014Purdue Pharma L.P.Tamper resistant dosage forms
US8821929May 23, 2013Sep 2, 2014Purdue Pharma L.P.Tamper resistant dosage forms
US8834925May 23, 2013Sep 16, 2014Purdue Pharma L.P.Tamper resistant dosage forms
US20110009834 *Feb 27, 2009Jan 13, 2011Lts Lohmann Therapie-Systeme AgGingival wafer
CN101489756BMar 22, 2007Aug 7, 2013奥克思利尤姆国际控股公司Process for the preparation of a hot-melt extruded laminate
EP0598606A1 *Nov 17, 1993May 25, 1994JOHNSON & JOHNSON CONSUMER PRODUCTS, INC.Extrudable compositions for topical or transdermal drug delivery
EP1659976A2 *May 7, 2004May 31, 2006Ultradent Products, Inc.Compositons and devices having a tray-like configuration for delivering an oral medicament and methods of manufacturing and using such compositions and devices
EP2010156A2 *Mar 22, 2007Jan 7, 2009Auxilium International Holdings, Inc.Stabilized compositions containing alkaline labile drugs
WO1992007640A1 *Sep 23, 1991May 14, 1992Fmc CorpPolysaccharide-based porous sheets
WO2007112285A2 *Mar 22, 2007Oct 4, 2007Auxilium Pharmaceuticals IncProcess for the preparation of a hot-melt extruded laminate
WO2011081625A1Dec 30, 2009Jul 7, 2011Novartis AgMelt extruded thin strips containing coated pharmaceutical actives
WO2011081628A1Dec 30, 2009Jul 7, 2011Novartis AgMelt extruded nicotine thin strips
Classifications
U.S. Classification424/676, 424/449, 424/435
International ClassificationA61K9/00
Cooperative ClassificationA61K9/006
European ClassificationA61K9/00M18D
Legal Events
DateCodeEventDescription
May 3, 1999FPAYFee payment
Year of fee payment: 12
May 25, 1995FPAYFee payment
Year of fee payment: 8
Jun 3, 1991FPAYFee payment
Year of fee payment: 4